Clinical trials: Refractory Soft Tissue Sarcomas, open to volunteers
Diagnosed or Relapsed/Refractory Sarcomas
Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas
Bone and soft tissue sarcomas represent about 7-12% of all pediatric cancer and are a heterogeneous group of tumors arising in connective tissues embryologically derived from the mesenchyme.
- Trial name
- NCT04621201
- Testing
- observation and biopsy
- Where
- 10 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
Recurrent Solid Tumor, Recurrent Ewing Sarcoma
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away).
- Conditions
- Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Malignant Germ Cell Tumor
- Trial name
- NCT04901702
- Testing
- Onivyde, Talazoparib, Temozolomide
- Where
- 10 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- St. Jude Children's Research Hospital
Relapsed Neuroblastoma, Refractory Neuroblastoma
NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
The purpose of this study is to find the largest safe dose of i15.NKG2D.zeta-NK cells in combination with C7R.GD2.CAR-T cells, and additionally to evaluate how long they can be detected in patients' blood and what affect they…
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
- Trial name
- NCT07211737
- Testing
- i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Baylor College of Medicine
Rhabdomyosarcoma
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
Background: Rhabdomyosarcoma (RMS) is a cancer of soft tissues. It is the most common soft tissue sarcoma seen in children. RMS cancer cells have a protein called FGFR4 on their surface.
- Trial name
- NCT06865664
- Testing
- fludarabine, cyclophosphamide, cetuximab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Ewing Sarcoma
RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT
The goal of this clinical research study is to learn if new anticancer drugs or drug combinations can help to control relapsed/refractory ES, DSRCT, or SRCS.
- Trial name
- NCT07781891
- Testing
- LX-101
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Osteosarcoma
A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
This is a phase 1/2 study evaluating safety, tolerability, and efficacy of Sulfatinib in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed osteosarcoma ( combination…
- Trial name
- NCT05590572
- Testing
- Sulfatinib, Etoposide, Isophosphamide
- Where
- 5 sites in China, South Korea
- Volunteers
- 148 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Neuroblastoma (NB), Desmoplastic Small Round Cell Tumor (DSRCT)
Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.
Title: Safety and efficacy of CAR-T cell therapy for relapsed/refractory neuroblastoma and desmoplastic small round cell tumors: a single-arm, open-label trial.
- Trial name
- NCT06836505
- Testing
- CART therapy
- Where
- 3 sites in China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-Sen University Cancer Center
Soft Tissue Sarcoma
tTF-NGR Randomized Study - STS
In this phase III open label, controlled clinical trial patients with unresectable or metastatic soft-tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs and CD13…
- Trial name
- TRABTRAP (NCT05597917)
- Testing
- Trabectedin, tTF-NGR
- Where
- 9 sites in Germany
- Volunteers
- 126 people
- Sponsor
- Universität Münster
Sarcoma, Sarcoma, Ewing
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
This research is being done to test a new drug called PEEL-224 in combination with two commercially available drugs, Vincristine and Temozolomide, and to determine how effective this combination of drugs is at treating Ewing…
- Conditions
- Sarcoma, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor, Refractory Sarcoma
- Trial name
- NCT06709495
- Testing
- PEEL-224, Temozolomide, Vincristine
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- David S Shulman, MD
Desmoplastic Small Round Cell Tumor, Osteosarcoma
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
This phase I/II trial studies the effects of trastuzumab deruxtecan (DS-8201a) in treating patients with osteosarcoma, Wilms tumor (WT) or desmoplastic small round cell tumor (DSRCT) that is newly diagnosed or has come back after…
- Conditions
- Desmoplastic Small Round Cell Tumor, Osteosarcoma, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Kidney Wilms Tumor
- Trial name
- NCT04616560
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 32 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Ewing Sarcoma
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric…
- Trial name
- NCT07297979
- Testing
- Xaluritamig
- Where
- 13 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- Amgen
Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard…
- Conditions
- Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma, BCC
- Trial name
- NCT05859074
- Testing
- MQ719, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
MPNST (Malignant Peripheral Nerve Sheath Tumor)
Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor
The purpose of this study is to learn whether the study drugs avutometinib and defactinib can help stop or shrink malignant peripheral nerve sheath tumors (MPNST) that have returned or cannot be removed with surgery.
- Trial name
- NF120 (NCT07743554)
- Testing
- avutometinib capsule + defactinib tablet
- Volunteers
- 25 people
- Sponsor
- Girish Dhall, MD
Sarcoma, Childhood Osteosarcoma
Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas
RAD3CAR is a phase I study designed to evaluatethe safety of B7-H3-CAR T cells and lymphodepletion in combination with hypofractionated radiation therapy.
- Conditions
- Sarcoma, Childhood Osteosarcoma, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma
- Trial name
- NCT07222735
- Testing
- Fludarabine, Cyclophosphamide, B7-H3-CAR T Cells
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- St. Jude Children's Research Hospital
Relapsed Sarcomas
Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
The purpose of this study is to test the safety of combining the disulfiram (DSF) and copper gluconate (Cu) to liposomal doxorubicin to treat patients with sarcomas that recurred or did not respond to initial treatment.
- Trial name
- NCT05210374
- Testing
- Disulfiram, Copper Gluconate, Liposomal Doxorubicin (Doxil)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Case Comprehensive Cancer Center
Recurrent or Refractory Solid Tumors, Ewing Sarcoma
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
This is a Phase 1 study of the combination of two drugs: MM-398 and Cyclophosphamide. The goal is to find the highest dose of MM-398 that can be given safely when it is used together with the chemotherapy drug Cyclophosphamide.
- Conditions
- Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma
- Trial name
- NCT02013336
- Testing
- MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- South Plains Oncology Consortium
Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors.
- Conditions
- Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT05039801
- Testing
- Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Osteosarcomas, Bone Cancer
Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.
Osteosarcomas, like other primitive bone tumors, remain hard-to-treat malignancies, especially after failure of first-line treatments.
- Conditions
- Osteosarcomas, Bone Cancer, Ewing Sarcomas
- Trial name
- BONE DINIRRA (NCT07853105)
- Testing
- Dinutuximab beta, Sirolimus and Irinotecan
- Where
- 12 sites in France
- Volunteers
- 89 people
- Sponsor
- University Hospital, Strasbourg, France
Neuroblastoma, Sarcoma
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
The purpose of this study is to test the manufacturing feasibility and safety of intravenous (IV) administration of B7-H3CART in children and young adult subjects with relapsed and/or refractory solid tumors expressing B7-H3…
- Conditions
- Neuroblastoma, Sarcoma, Osteosarcoma
- Trial name
- NCT06500819
- Testing
- B7-H3CART Dose (Intravenous)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Stanford University
Advanced Solid Tumors, Ovarian Cancer
A Study of PHST001 in Advanced Solid Tumors
This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination…
- Conditions
- Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma
- Trial name
- NCT06840886
- Testing
- PHST001, Paclitaxel, Topotecan
- Where
- 20 sites in United States
- Volunteers
- 426 people
- Sponsor
- Pheast Therapeutics